6-chloro-5-cyclohexyl-2,3-dihydro-1H-indene-1-carboxylic acid;2-[[4-(4-chlorophenyl)phenyl]methoxy]-2-methylpropanoic acid;N-hydroxy-2-(5-methoxy-2-methyl-1H-indol-3-yl)acetamide

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 6-chloro-5-cyclohexyl-2,3-dihydro-1H-indene-1-carboxylic acid;2-[[4-(4-chlorophenyl)phenyl]methoxy]-2-methylpropanoic acid;N-hydroxy-2-(5-methoxy-2-methyl-1H-indol-3-yl)acetamide
• 化学式: C45H50Cl2N2O8
• 分子量: 817.8
• InChiKey: IZZILYPTEQTNQQ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  10.42
• 重原子数：
  57
• 可旋转键数：
  10
• 环数：
  7.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  158
• 氢给体数：
  5
• 氢受体数：
  8

文献信息

• [EN] HETEROARYL SUBSTITUTED SPIROPIPERIDINYL DERIVATIVES AND PHARMACEUTICAL USES THEREOF<br/>[FR] DÉRIVÉS DE SPIROPIPÉRIDINYLE SUBSTITUÉS PAR HÉTÉROARYLE ET LEURS UTILISATIONS PHARMACEUTIQUES
  申请人：NOVARTIS AG

  公开号：WO2022034529A1

  公开（公告）日：2022-02-17

  The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof; (I) wherein R1 R2, R4 and X1 are defeined herein, a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.

  本发明提供了化合物(I)或其药用可接受盐；(I)中R1、R2、R4和X1的定义见本文，本发明化合物的制备方法以及其治疗用途。本发明还提供了药理活性剂的组合和药物组合物。
• [EN] NLRP3 INFLAMMASOME INHIBITORS<br/>[FR] INHIBITEURS D'INFLAMMASOME NLRP3
  申请人：NOVARTIS AG

  公开号：WO2020021447A1

  公开（公告）日：2020-01-30

  The present invention relates to novel thienopyrrolotriazinacetamide compounds of Formula (I): wherein R1, R2 and R3 are defined herein, which inhibit NOD-like receptor protein 3 (NLRP3) inflammasome activity. The invention further relates to the processes for their preparation, pharmaceutical compositions and medicaments containing them, and their use in the treatment of diseases and disorders mediated by NLRP3.

  本发明涉及一种新型噻吡咯三唑酰胺化合物的化学式（I）：其中R1、R2和R3如本文所定义，该化合物抑制NOD样受体蛋白3（NLRP3）炎症小体活性。该发明还涉及它们的制备过程、含有它们的药物组合物和药物，以及它们在治疗由NLRP3介导的疾病和紊乱中的用途。
• NLRP3 INFLAMMASOME INHIBITORS
  申请人：Novartis AG

  公开号：US20200361898A1

  公开（公告）日：2020-11-19

  The present invention relates to novel pyridazin-3-yl phenol compounds of Formula (I): wherein R 1 , R 2 , R 3 , R 4 , R 5 and Z are defined herein, which inhibit NOD-like receptor protein 3 (NLRP3) inflammasome activity. The invention further relates to the processes for their preparation, pharmaceutical compositions and medicaments containing them, and their use in the treatment of diseases and disorders mediated by NLRP3.

  本发明涉及一种新型吡啶并[3,4-d]嘧啶-3-基酚类化合物，其化学式为(I)：其中R1、R2、R3、R4、R5和Z在此处定义，可抑制NOD样受体蛋白3（NLRP3）炎症小体活性。该发明还涉及其制备过程、含有它们的药物组合物和药物，以及它们在治疗由NLRP3介导的疾病和紊乱中的应用。
• [EN] INTERLEUKIN-17 INHIBITORS<br/>[FR] INHIBITEURS DE L'INTERLEUKINE-17
  申请人：NOVARTIS AG

  公开号：WO2022091056A1

  公开（公告）日：2022-05-05

  The present invention relates to novel pyridine-N oxide substituted 2-formamido (N-phenyl and N-pyridyl) acetamide compounds that are Interleukin-17 (IL-17) inhibitors, processes for their preparation, pharmaceutical compositions, and medicaments containing them, and their use in diseases and disorders mediated by IL-17.

  本发明涉及新型吡啶-N氧化物取代的2-甲酰胺（N-苯基和N-吡啶基）乙酰胺化合物，它们是白细胞介素-17（IL-17）抑制剂，包括它们的制备方法、制药组合物以及含有它们的药物，以及它们在由IL-17介导的疾病和障碍中的应用。
• ROFLUMILAST N-OXIDE FOR USE IN TREATING AUTOIMMUNE, RESPIRATORY AND INFLAMMATORY DISORDERS BY INHALATION
  申请人：Incozen Therapeutics Pvt. Ltd.

  公开号：EP3763366A1

  公开（公告）日：2021-01-13

  The present disclosure relates to pharmaceutical compositions useful for (and to a method of) treating autoimmune, respiratory and/or inflammatory diseases and conditions. The method involves administering to a subject in need thereof roflumilast N-oxide by inhalation. The present disclosure particularly relates to the treatment of asthma and chronic obstructive pulmonary disease (COPD) by administering roflumilast N-oxide by inhalation.

  本公开涉及可用于治疗自身免疫性、呼吸道和/或炎症性疾病和病症的药物组合物（以及治疗方法）。该方法包括通过吸入给需要的受试者施用罗氟司特N-氧化物。本公开尤其涉及通过吸入罗氟司特N-氧化物治疗哮喘和慢性阻塞性肺病（COPD）。